Raymond James Financial
LXRX icon

Raymond James Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

Raymond James Financial’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,076
Closed -$1.96K – 5976
2025
Q2 		$1.96K Sell
2,076
-9,836
-83% -$6.37K ﹤0.01% 6416
2025
Q1 		$5.49K Hold
11,912
– – ﹤0.01% 4797
2024
Q4 		$8.8K Buy
+11,912
New +$14.4K ﹤0.01% 4778

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's LXRX Position: Q3 2025 in Review

Raymond James Financial sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2025, closing a stake of 2,076 shares — an estimated $1.96K sold.

Raymond James Financial first reported a position in LXRX in Q4 2024 and held it in 3 quarters. The position peaked at $8.8K in Q4 2024. 123 funds tracked by Wall St. Rank hold LXRX as of Q3 2025.

  • Raymond James Financial reported no remaining Lexicon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,076 Lexicon Pharmaceuticals shares in Q3 2025, an estimated $1.96K.
  • Raymond James Financial first reported a position in Lexicon Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Raymond James Financial's Lexicon Pharmaceuticals position peaked at $8.8K in Q4 2024.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.